MX2024012095A - Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiátricos y neurológicos - Google Patents
Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiátricos y neurológicosInfo
- Publication number
- MX2024012095A MX2024012095A MX2024012095A MX2024012095A MX2024012095A MX 2024012095 A MX2024012095 A MX 2024012095A MX 2024012095 A MX2024012095 A MX 2024012095A MX 2024012095 A MX2024012095 A MX 2024012095A MX 2024012095 A MX2024012095 A MX 2024012095A
- Authority
- MX
- Mexico
- Prior art keywords
- psychoactive
- disorders
- medicines
- neurological conditions
- treating psychiatric
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 230000000926 neurological effect Effects 0.000 title abstract 2
- USWVWJSAJAEEHQ-UHFFFAOYSA-N 1,3-benzodioxolyl-n-methylbutanamine Chemical compound CCC(NC)CC1=CC=C2OCOC2=C1 USWVWJSAJAEEHQ-UHFFFAOYSA-N 0.000 abstract 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 abstract 1
- 150000008367 cathinones Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325757P | 2022-03-31 | 2022-03-31 | |
| US202263328343P | 2022-04-07 | 2022-04-07 | |
| PCT/US2022/074369 WO2023015154A1 (en) | 2021-08-06 | 2022-08-01 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| US202363437000P | 2023-01-04 | 2023-01-04 | |
| PCT/US2023/012196 WO2023191952A1 (en) | 2022-03-31 | 2023-02-02 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012095A true MX2024012095A (es) | 2025-01-09 |
Family
ID=88203364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012095A MX2024012095A (es) | 2022-03-31 | 2024-09-30 | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiátricos y neurológicos |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4499066A4 (https=) |
| JP (1) | JP2025510790A (https=) |
| KR (1) | KR20240165982A (https=) |
| CN (1) | CN119095593A (https=) |
| AU (1) | AU2023241546A1 (https=) |
| CA (1) | CA3254727A1 (https=) |
| IL (1) | IL315832A (https=) |
| MX (1) | MX2024012095A (https=) |
| TW (1) | TW202345789A (https=) |
| WO (1) | WO2023191952A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120379978A (zh) * | 2022-10-20 | 2025-07-25 | 创见疗法股份有限公司 | 苯乙胺和卡西酮及其立体异构体与其前体的制备 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039133A1 (en) * | 1995-06-06 | 1996-12-12 | Neurobiological Technologies, Inc. | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones |
| US8575194B1 (en) * | 2004-08-31 | 2013-11-05 | Jack William Schultz | Treatment methods of cognitive, emotional and mental ailments and disorders |
| EP2931291B1 (en) * | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| WO2017151980A1 (en) * | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| WO2021257500A1 (en) * | 2020-06-17 | 2021-12-23 | Lobe Sciences Ltd. | Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder |
| JP2024512796A (ja) * | 2021-04-01 | 2024-03-19 | テラン バイオサイエンシーズ インク． | サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物 |
| MX2024001654A (es) * | 2021-08-06 | 2024-06-28 | Transcend Therapeutics Inc | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
| AU2022330718B2 (en) * | 2021-08-20 | 2026-02-19 | Pharmala Biotech Inc. | Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof |
| WO2023081899A1 (en) * | 2021-11-05 | 2023-05-11 | Terran Biosciences, Inc. | Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof |
| EP4426685A4 (en) * | 2021-11-05 | 2026-01-07 | Terran Biosciences Inc | Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use |
| CA3239514A1 (en) * | 2021-12-09 | 2023-06-15 | Matthew J. Baggott | Specialized combinations for mental disorders or mental enhancement |
-
2023
- 2023-02-02 KR KR1020247034657A patent/KR20240165982A/ko active Pending
- 2023-02-02 JP JP2024556474A patent/JP2025510790A/ja active Pending
- 2023-02-02 CN CN202380031652.9A patent/CN119095593A/zh active Pending
- 2023-02-02 WO PCT/US2023/012196 patent/WO2023191952A1/en not_active Ceased
- 2023-02-02 EP EP23781540.2A patent/EP4499066A4/en active Pending
- 2023-02-02 CA CA3254727A patent/CA3254727A1/en active Pending
- 2023-02-02 IL IL315832A patent/IL315832A/en unknown
- 2023-02-02 AU AU2023241546A patent/AU2023241546A1/en active Pending
- 2023-02-06 TW TW112104131A patent/TW202345789A/zh unknown
-
2024
- 2024-09-30 MX MX2024012095A patent/MX2024012095A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240165982A (ko) | 2024-11-25 |
| IL315832A (en) | 2024-11-01 |
| CN119095593A (zh) | 2024-12-06 |
| WO2023191952A1 (en) | 2023-10-05 |
| CA3254727A1 (en) | 2023-10-05 |
| JP2025510790A (ja) | 2025-04-15 |
| TW202345789A (zh) | 2023-12-01 |
| EP4499066A4 (en) | 2026-02-18 |
| AU2023241546A1 (en) | 2024-10-17 |
| EP4499066A1 (en) | 2025-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001654A (es) | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. | |
| ZA202107444B (en) | Nlrp3 inflammasome inhibitors | |
| MX2021000925A (es) | Inhibidores de inflamasoma nlrp3. | |
| PH12020550341A1 (en) | Niraparib formulations | |
| MX2024012095A (es) | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiátricos y neurológicos | |
| PH12021550381A1 (en) | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | |
| PH12020552111A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| JOP20220235A1 (ar) | 3-فينوكسي أزيتيدين-1-يل بيرازينات مستبدلة لديها نشاط ناهض لـ gpr52 | |
| JOP20240053A1 (ar) | أملاح ناهض sstr4 | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| JOP20200079A1 (ar) | مثبطات مستقبل عامل نمو البشرة | |
| WO2020145831A8 (en) | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases | |
| PH12021550957A1 (en) | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | |
| HN2001000218A (es) | Un efecto compuesto derivado de la triptamina y sus analogos | |
| CR20240353A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| WO2024254190A3 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| GEP20247629B (en) | Alcohol derivatives as kv7 potassium channel openers | |
| CL2024000893A1 (es) | Derivados de amina bicíclicos como moduladores de receptor gabaa alfa5 | |
| JOP20240175A1 (ar) | مركبات بيرازولو بيريميدين، وتركيبات تشتمل عليها واستخداماتها | |
| MX2025014366A (es) | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiátricos y neurológicos | |
| EP4009949A4 (en) | OLFACTORY DELIVERY OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM | |
| MX2021007562A (es) | Analogos de pentamidina y usos para estos. | |
| EP4527384A3 (en) | Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders | |
| AR127170A1 (es) | Antagonistas del receptor de la hormona paratiroidea (pth) y sus usos |